The immune system comprises a diverse array of cells, including T cells, B cells, Natural Killer (NK) cells, and Dendritic Cells (DCs). T cells play a pivotal role in adaptive immune responses and are broadly classified into two categories based on their surface receptors: αβT cells and γδT cells. While αβT cells rely on the Major Histocompatibility Complex (MHC) for antigen recognition, γδT cells are MHC-independent, possessing unique immunological functions and participating in a wide range of immune reactions.

γδT cells are a distinct T cell subset characterized by the expression of the γδ heterodimer T cell receptor (TCRγδ) on their surface. Constituting 1% to 5% of peripheral blood T lymphocytes, they are primarily found in mucosal tissues such as the skin, respiratory tract, digestive tract, and uterus. Compared to αβT cells, which are involved in adaptive immunity, γδT cells do not require MHC participation to recognize tumor antigens. They inherently possess antigen-presenting capabilities. Depending on the tumor microenvironment, different γδT subgroups can exhibit either anti-tumor or pro-tumor activity. They eliminate tumor cells by recognizing tumor-associated antigens via TCRγδ and can further bolster the anti-tumor capacity of other immune cells by secreting cytokines or expressing co-stimulatory molecules.

As research deepens, immunotherapy has emerged as the fourth pillar of cancer treatment, following surgery, chemotherapy, and radiotherapy. While T cell and NK cell immunotherapies are nearing maturity, γδT cell immunotherapy has become a new research hotspot due to its unique advantages in combating tumors. However, since γδT cells constitute a very small fraction of peripheral blood T lymphocytes, achieving high purity and efficient in vitro expansion has remained a primary bottleneck restricting the development of γδT cell immunotherapy.The core R&D team at Shenzhen Cell Valley successfully tackled key challenges in their underlying technologies, achieving a breakthrough in γδT cell culture processes. With this new method, no sorting operation is required. After 15 days of culture, the purity of γδT cells stabilizes at over 95–99%, with a proliferation rate exceeding 600-fold.Furthermore, CAR-γδT cells produced using the Cell Valley's proprietary PackRV-SS retroviral vector technology achieved a transduction positive rate of approximately 60%, demonstrating potent anti-tumor activity.Shenzhen Cell Valley welcomes enterprises and institutions currently engaged in or intending to explore γδT cell therapy to collaborate with us in advancing the development of the industry.

 γδT Cell Performance：In a 15-day culture period, γδT cells achieved a purity of 99.6% and expanded by 666.05-fold. Furthermore, they demonstrated superior cytotoxicity compared to unactivated PanT cells.

CAR-γδT Cell Performance：Similar to T cells and NK cells, γδT cells can be engineered into CAR-γδT cells to enhance their tumor-killing efficacy. Using Shenzhen Cell Valley’s proprietary BaEV envelope technology for retroviral vector production, the transduction positive rate of CAR-γδT cells reached 62.2%, with a cell purity exceeding 95%. Notably, these CAR-γδT cells exhibited significantly enhanced cytotoxicity compared to non-transduced γδT cells.

As T cell and NK cell therapies approach market saturation, γδT cell therapy is poised to become the next hotspot in cell therapy due to its unique advantages in oncology. Shenzhen Cell Valley is committed to focusing on solid tumor treatment, developing novel targets, optimizing culture processes, and exploring combination therapies. Leveraging the significant advantages of retroviral vectors in both research and industrial-scale production, we aim to co-develop cell products based on these vectors and jointly drive the advancement of next-generation cellular therapies.